Security record · archived quarter
CRNX
Crinetics Pharmaceuticals, Inc. · Healthcare · Biotechnology
15Tracked holders
0Δ holders
56.94MShares held
$2.37BReported value
+0New positions
−0Exits
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +2.9% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 89 | -1 | 71.70M | $2.68B | +5 | −6 |
| Q1 2026 | 93 | +2 | 73.05M | $2.65B | +9 | −7 |
| Q4 2025 | 90 | 0 | 75.54M | $3.52B | n/a | n/a |
| Q3 2025 | 15 | 0 | 56.94M | $2.37B | n/a | n/a |
| Q2 2025 | 12 | 0 | 51.44M | $1.48B | +1 | −1 |
| Q1 2025 | 9 | -2 | 19.08M | $640.10M | +2 | −4 |
| Q4 2024 | 11 | -1 | 21.01M | $1.07B | n/a | −1 |
| Q3 2024 | 11 | -2 | 14.60M | $745.98M | n/a | −2 |
| Q2 2024 | 13 | n/a | 14.80M | $663.11M | n/a | n/a |
Who holds it · Q3 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 14.19M | +0.4% | $590.91M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | The Vanguard Group ✦ (passive) | 9.17M | -0.9% | $381.94M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | Wellington Management ✦ | 8.38M | +44.3% | $349.11M | 0.1% | ▲ Add | 6 | SEC ↗ ×7 |
| 4 | BlackRock ✦ (passive) | 7.59M | +2.3% | $315.98M | 0.0% | ▲ Add | 2 | SEC ↗ ×16 |
| 5 | T. Rowe Price ✦ | 5.31M | -5.1% | $221.01M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 6 | JPMorgan Chase ✦ | 2.52M | n/a | $104.85M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 7 | Geode Capital Management ✦ (passive) | 2.28M | +3.0% | $94.93M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | State Street Global Advisors ✦ (passive) | 2.21M | -31.5% | $91.95M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | Point72 Asset Management ✦ | 2.00M | +0.3% | $83.44M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 884.51K | +35.3% | $36.84M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | Fisher Asset Management ✦ | 758.36K | +2.9% | $31.59M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 12 | Goldman Sachs Group ✦ | 713.13K | n/a | $29.70M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 13 | Morgan Stanley ✦ | 682.13K | n/a | $28.41M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 14 | Millennium Management ✦ | 216.24K | -39.5% | $9.01M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 49.70K | -5.8% | $2.07M | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 241 holders, 121.45M shares, $4.08B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Aug 13
SC 13G/A: WELLINGTON MANAGEMENT GROUP LLP
Aug 07
SC 13G/A: FMR LLC
Aug 03
SC 13G/A: FARALLON CAPITAL MANAGEMENT, L.L.C.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2025 ·
Methodology ·
Get this via the API